Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.
Alesta Therapeutics has raised $67.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Alesta Therapeutics's investors include RTW Investments, Frazier Life Sciences, Novartis Venture Fund, Thuja Capital, Droia Ventures.
Alesta Therapeutics is headquartered in Leiden, The Netherlands.
Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.
Alesta Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alesta Therapeutics — Funding & Investors." VCBacked, January 8, 2025, https://www.vcbacked.co/company/alesta-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Alesta Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/alesta-therapeutics
{{cite web |title=Alesta Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alesta-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated